Pharmaceuticals & Therapeutics

Vancouver's ME Therapeutics will unveil its in-vivo immune reprogramming technology, a potential cancer treatment game-changer, to global investors.

A massive $250M investment could replace a 40-pill daily burden with a single tablet for patients with pancreatic insufficiency, disrupting a market in crisis.

A landmark European trial for a new genomic test has passed 50% recruitment, promising to tailor breast cancer therapy and improve patient quality of life.

Fueled by a $100M R&D investment, Chinese beauty giant Yatsen is leading a market shift from price wars to scientific innovation, winning global consumers.

The diagnostics firm's stellar quarter is fueled by surging test volumes and a new non-invasive prenatal test poised to disrupt high-risk screening.

As Walmart Canada launches its annual campaign for kids' health, a look at how decades of donations address critical gaps in a strained medical system.

Diathrive Health and AliveCor's KardiaComplete partner to offer an integrated solution for diabetes and heart disease, combating fragmented care and rising costs.

Co-founded by Maria Shriver, MOSH raises $13M to scale its brain health nutrition brand, targeting a national grocery and Target rollout.

Pet Honesty launches "The Honest Difference," a new standard for supplement transparency, and pledges a $1M product donation to pets in need.

RVL Pharmaceuticals claims double-digit growth for its eye drop Upneeq, but as a private firm, its disruptive direct-to-consumer model operates outside public view.

A new global partnership aims to solve key bottlenecks in regenerative medicine by providing standardized, high-quality umbilical cord stem cells to researchers.

Alcami acquires Tjoapack, creating a transatlantic CDMO. The deal, orchestrated by owner Ampersand Capital, signals a major shift in pharma services.

The Sugar Ray Leonard Foundation's 15th annual charity boxing night will honor Dr. Jennifer Raymond for her groundbreaking work in pediatric diabetes care.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

Sensei Biotherapeutics begins a key trial for PIKTOR, a novel oral therapy aiming to outsmart cancer resistance in patients with advanced breast cancer.

Minerva Neurosciences launches a pivotal Phase 3 trial for roluperidone, a potential first-in-class drug for the untreated negative symptoms of schizophrenia.

A new FDA-cleared shoulder implant from FX Shoulder Solutions offers unprecedented flexibility, allowing surgeons to adapt their approach mid-surgery.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.